scholarly journals In vitro activity of voriconazole and amphotericin B against Candida albicans, Candida krusei, and Cryptococcus neoformans in human cerebrospinal fluid

Infection ◽  
2019 ◽  
Vol 47 (4) ◽  
pp. 565-570 ◽  
Author(s):  
Valentin al Jalali ◽  
Robert Sauermann ◽  
Sabine Eberl ◽  
Markus Zeitlinger
Keyword(s):  
Cerebrospinal Fluid ◽  
Candida Albicans ◽  
Cryptococcus Neoformans ◽  
Amphotericin B ◽  
Candida Krusei ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Human Cerebrospinal Fluid

scholarly journals In Vitro Activity of a New Polyene, SPA-S-843, against Yeasts

1998 ◽  
Vol 42 (11) ◽  
pp. 3012-3013 ◽  
Author(s):  
C. Rimaroli ◽  
T. Bruzzese
Keyword(s):  
Candida Albicans ◽  
Amphotericin B ◽  
Candida Tropicalis ◽  
Candida Glabrata ◽  
Fungicidal Activity ◽  
Candida Krusei ◽  
Water Soluble ◽  
Vitro Activity ◽  
In Vitro Activity

ABSTRACT The in vitro activity of a new water-soluble polyene, SPA-S-843, was evaluated against 116 strains of Candida,Cryptococcus, and Saccharomyces spp. and compared with that of amphotericin B. SPA-S-843 demonstrated better inhibitory activity against all of the yeasts examined and better fungicidal activity against Candida albicans, Candida glabrata, Candida krusei, and Candida tropicalis than did amphotericin B.

scholarly journals In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates.

1997 ◽  
Vol 41 (5) ◽  
pp. 1156-1157 ◽  
Author(s):  
O Uzun ◽  
S Kocagöz ◽  
Y Cetinkaya ◽  
S Arikan ◽  
S Unal
Keyword(s):  
Candida Albicans ◽  
Amphotericin B ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Broth Microdilution ◽  
Microdilution Method ◽  
Broth Microdilution Method

The in vitro activity of LY303366, a new echinocandin derivative, was evaluated with 191 yeast isolates by a broth microdilution method. The MICs at which 50% of the isolates were inhibited were 0.125 microg/ml for Candida albicans and C. tropicalis, 0.25 microg/ml for C. krusei, C. kefyr, and C. glabrata, and 2.0 microg/ml for C. parapsilosis.

P1956 In vitro activity of amphotericin B and anidulafungin against Candida albicans biofilms

2007 ◽  
Vol 29 ◽  
pp. S562
Author(s):  
A. Valentín ◽  
E. Cantóon ◽  
J. Pemáan ◽  
M. Bosch ◽  
E. Eraso ◽  
...  
Keyword(s):  
Candida Albicans ◽  
Amphotericin B ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Candida Albicans Biofilms

scholarly journals In Vitro Activities of Voriconazole, Fluconazole, and Itraconazole against 566 Clinical Isolates of Cryptococcus neoformans from the United States and Africa

1999 ◽  
Vol 43 (1) ◽  
pp. 169-171 ◽  
Author(s):  
M. A. Pfaller ◽  
J. Zhang ◽  
S. A. Messer ◽  
M. E. Brandt ◽  
R. A. Hajjeh ◽  
...  
Keyword(s):  
United States ◽  
Cerebrospinal Fluid ◽  
Cryptococcus Neoformans ◽  
The United States ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Almost All

ABSTRACT We investigated the in vitro activity of voriconazole compared to those of fluconazole and itraconazole against 566 clinical isolates ofCryptococcus neoformans from Africa (164) and the United States (402). Isolates were obtained from cerebrospinal fluid (362), blood (139), and miscellaneous sites (65). Voriconazole (MIC at which 90% of the isolates are inhibited [MIC90], 0.12 to 0.25 μg/ml) was more active than either itraconazole (MIC90, 0.5 μg/ml) or fluconazole (MIC90, 8.0 to 16 μg/ml) against both African and U.S. isolates. Isolates inhibited by ≥16 μg of fluconazole per ml were almost all (99%) inhibited by ≤1 μg of voriconazole per ml. These results suggest that voriconazole may be useful in the treatment of cryptococcosis.

scholarly journals Comparative Antifungal Activity of Cilofungin (LY121019) againstCandidaSpecies, Including Evaluation of Susceptibility Testing Method

1992 ◽  
Vol 3 (5) ◽  
pp. 231-234 ◽  
Author(s):  
Abdul H Chagla ◽  
John H Hii ◽  
Daryl J Hoban ◽  
Andrew E Simor ◽  
Santiago Ferro ◽  
...  
Keyword(s):  
Candida Albicans ◽  
Amphotericin B ◽  
Candida Glabrata ◽  
Susceptibility Testing ◽  
Inhibitory Concentration ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Testing Method ◽  
Testing Susceptibility

The in vitro activity of cilofungin against 100Candidaspecies was compared with 5-flucytosine. amphotericin B and ketoconazole by two laboratories independently and in a blinded fashion using a macrotitre dilution broth method insaam-fmedium. Cilofungin showed good in vitro activity againstCandida albicans. Candida tropicalisandCandida glabrata(90% minimal inhibitory concentration [MIC] 3.2 μg/mL) but was inactive against otherCandidaspecies. When testing the susceptibility of cilofungin, 5-flucytosine and amphotericin B at the two centres, approximately 90% of theCandidastrains had MICs differing by fourfold or less. However, when testing susceptibility of ketoconazole, only 51% of theCandidastrains had MIC differences fourfold or less. MIC susceptibility testing with cilofungin, 5-flucytosine and amphotericin B insaam-fmedium is reproducible.

scholarly journals In Vitro Activity of the New Azole Isavuconazole (BAL4815) Compared with Six Other Antifungal Agents against 162 Cryptococcus neoformans Isolates from Cuba

2008 ◽  
Vol 52 (4) ◽  
pp. 1580-1582 ◽  
Author(s):  
Maria-Teresa Illnait-Zaragozi ◽  
Gerardo F. Martínez ◽  
Ilse Curfs-Breuker ◽  
Carlos M. Fernández ◽  
Teun Boekhout ◽  
...  
Keyword(s):  
Cryptococcus Neoformans ◽  
Amphotericin B ◽  
Antifungal Agents ◽  
Vitro Activity ◽  
In Vitro Activity

ABSTRACT Cuban Cryptococcus isolates (n = 165) were tested in vitro against amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole, giving MIC90 values of 0.25, 8, 4, 0.25, 0.125, 0.016, and 0.016 μg/ml, respectively. Isavuconazole and posaconazole seem to be potentially active drugs for treating cryptococcal infections.

scholarly journals In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.

1996 ◽  
Vol 40 (8) ◽  
pp. 1910-1913 ◽  
Author(s):  
J R Perfect ◽  
G M Cox ◽  
R K Dodge ◽  
W A Schell
Keyword(s):  
Central Nervous System ◽  
Cryptococcus Neoformans ◽  
Amphotericin B ◽  
Central Nervous System Infection ◽  
Rabbit Model ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Drug Concentrations

Multiple isolates of Cryptococcus neoformans were tested to compare the in vitro activity of a new triazole, SCH56592, with those of amphotericin B, fluconazole, and itraconazole, MICs of each drug were determined, and minimum fungicidal concentrations of SCH56592 and amphotericin B were measured. MICs of SCH56592 were lower than those of amphotericin B and fluconazole but not those of itraconazole. Minimum fungicidal concentrations of SCH56592 were lower than those of amphotericin B. SCH56592 in the presence of human serum produces an in vitro fungicidal effect for Cryptococcus neoformans. The data indicate that SCH56592 might exert fungicidal as well as inhibitory properties in vivo. On the basis of these results, SCH56592 was evaluated with a rabbit model of experimental cryptococcal meningitis; SCH56592 treatment was compared with treatment with fluconazole. Despite no detectable drug concentrations in the cerebrospinal fluid, the activity of SCH56592 against C. neoformans infection was equivalent to that of fluconazole. SCH56592 has potent in vitro activity against C. neoformans and compares favorably to treatment with fluconazole for a central nervous system infection. SCH56592 should be studied for use in humans with cryptococcal infections.

Sign in / Sign up

Export Citation Format

Share Document